华仁药业(300110) - 2025 Q1 - 季度财报

Financial Performance - Revenue for Q1 2025 was CNY 303,472,326.57, a decrease of 25.38% compared to CNY 406,703,155.73 in the same period last year[2] - Net profit attributable to shareholders was CNY 16,028,449.64, down 68.46% from CNY 50,822,916.88 year-on-year[2] - Basic and diluted earnings per share were CNY 0.0136, a decline of 68.37% compared to CNY 0.0430 in the same period last year[2] - Total operating revenue decreased to ¥303,472,326.57 from ¥406,703,155.73, representing a decline of approximately 25.4% year-over-year[19] - Net profit for the period was ¥16,546,629.04, down from ¥52,378,184.34, reflecting a decline of approximately 68.4% year-over-year[20] - Operating profit decreased to ¥17,262,979.02 from ¥58,680,286.50, a drop of around 70.7% year-over-year[20] - The company reported a total comprehensive income of ¥16,546,629.04, down from ¥52,378,184.34, reflecting a decrease of about 68.4% year-over-year[20] Cash Flow and Investments - Net cash flow from operating activities decreased by 12.52% to CNY 96,675,551.41 from CNY 110,516,832.89 in the previous year[2] - The net cash flow from investment activities was negative CNY 25,822,417.54, a 114.37% increase in outflow compared to the previous year[9] - Cash flow from operating activities was ¥96,675,551.41, down from ¥110,516,832.89, a decrease of about 12.5% year-over-year[22] - The company incurred a net cash outflow from investing activities of ¥25,822,417.54, compared to a net outflow of ¥12,045,611.27 in the previous period[22] - The net cash outflow from financing activities was ¥54,282,863.33, an improvement from a net outflow of ¥221,122,266.65 in the previous period[23] Assets and Liabilities - Total assets increased by 0.64% to CNY 3,450,164,134.38 from CNY 3,428,120,079.39 at the end of the previous year[2] - As of March 31, 2025, the total assets of the company amounted to RMB 3,450,164,134.38, an increase from RMB 3,428,120,079.39 at the beginning of the period[17] - The total liabilities of the company were RMB 2,059,689,165.99, compared to RMB 2,054,191,740.04 at the beginning of the period, showing a slight increase of 0.27%[17] - The company's inventory decreased to RMB 281,481,226.88 from RMB 318,237,397.12, a decline of approximately 11.5%[16] - The company's long-term borrowings decreased to RMB 392,825,250.00 from RMB 464,080,000.00, a reduction of approximately 15.4%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 43,490[10] - The total equity attributable to the parent company increased to RMB 1,316,814,738.65 from RMB 1,300,786,289.01, reflecting a growth of about 1.2%[18] Other Financial Metrics - The company reported a significant increase in accounts receivable by 189.58% to CNY 10,281,791.52 due to the receipt of certain bills[6] - The company experienced a 12,213.08% increase in other operating income, totaling CNY 2,118,208.88, primarily due to the write-off of long-term payables[8] - The company’s weighted average return on equity decreased to 1.22% from 1.87% year-on-year[2] - The company has fully provided for credit impairment losses on receivables from a subsidiary, indicating a cautious approach to financial management[13] - The company is in the process of executing a debt resolution framework with a partner, which remains uncertain and subject to further evaluation[14]